156 215

Cited 54 times in

Polymorphisms associated with resistance and cross-resistance to aminoglycosides and capreomycin in Mycobacterium tuberculosis isolates from South Korean Patients with drug-resistant tuberculosis

DC FieldValueLanguage
dc.contributor.author김영미-
dc.contributor.author조상래-
dc.date.accessioned2015-04-23T16:26:19Z-
dc.date.available2015-04-23T16:26:19Z-
dc.date.issued2010-
dc.identifier.issn0095-1137-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/100582-
dc.description.abstractThe aminoglycosides streptomycin, amikacin, and kanamycin and the cyclic polypeptide capreomycin are all widely used in second-line therapy for patients who develop multidrug-resistant tuberculosis. We have characterized a set of 106 clinical isolates of Mycobacterium tuberculosis using phenotypic drug susceptibility testing (DST) to determine the extent of resistance to each agent and cross-resistance between agents. These results were compared with polymorphisms in the DNA sequences of ribosome-associated genes previously implicated in resistance and with the clinical outcomes of subjects from whom these isolates were obtained. Thirty-six (34%) of these isolates displayed resistance to one or more of these agents, and the majority of these (20 of 36) showed cross-resistance to one or more agents. Most (33 of 36) of the resistant isolates showed polymorphisms in the 16S ribosome components RpsL and rrs. Three resistant strains (3 of 36) were identified that had no known polymorphisms in ribosomal constituents. For kanamycin and streptomycin, molecular DST significantly outperformed phenotypic DST using the absolute concentration method for predicting 4-month sputum conversion (likelihood ratios of 4.0 and 2.0, respectively) and was equivalent to phenotypic DST using the National Committee for Clinical Laboratory Standards (NCCLS)-approved agar proportion method for estimating MIC (likelihood ratio, 4.0). These results offer insight into mechanisms of resistance and cross-resistance among these agents and suggest that the development of rapid molecular tests to distinguish polymorphisms would significantly enhance clinical utility of this important class of second-line antituberculosis drugs.-
dc.description.statementOfResponsibilityopen-
dc.format.extent402~411-
dc.relation.isPartOfJOURNAL OF CLINICAL MICROBIOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAminoglycosides/pharmacology*-
dc.subject.MESHAminoglycosides/therapeutic use-
dc.subject.MESHAntitubercular Agents/pharmacology*-
dc.subject.MESHAntitubercular Agents/therapeutic use-
dc.subject.MESHBacterial Proteins/genetics-
dc.subject.MESHCapreomycin/pharmacology*-
dc.subject.MESHCapreomycin/therapeutic use-
dc.subject.MESHDNA Mutational Analysis-
dc.subject.MESHDrug Resistance, Bacterial*-
dc.subject.MESHGenes, Bacterial-
dc.subject.MESHGenes, rRNA-
dc.subject.MESHHumans-
dc.subject.MESHMicrobial Sensitivity Tests-
dc.subject.MESHMycobacterium tuberculosis/drug effects*-
dc.subject.MESHMycobacterium tuberculosis/isolation & purification-
dc.subject.MESHPolymorphism, Genetic*-
dc.subject.MESHRepublic of Korea-
dc.subject.MESHRibosomal Proteins/genetics-
dc.subject.MESHTreatment Outcome-
dc.subject.MESHTuberculosis, Multidrug-Resistant/drug therapy-
dc.subject.MESHTuberculosis, Multidrug-Resistant/microbiology*-
dc.titlePolymorphisms associated with resistance and cross-resistance to aminoglycosides and capreomycin in Mycobacterium tuberculosis isolates from South Korean Patients with drug-resistant tuberculosis-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Microbiology & Immunology (미생물학)-
dc.contributor.googleauthorLaura E. Via-
dc.contributor.googleauthorSang-Nae Cho-
dc.contributor.googleauthorSoohee Hwang-
dc.contributor.googleauthorHyeeun Bang-
dc.contributor.googleauthorSeung Kyu Park-
dc.contributor.googleauthorHyung Seok Kang-
dc.contributor.googleauthorDoosoo Jeon-
dc.contributor.googleauthorSeon Yeong Min-
dc.contributor.googleauthorTaegwon Oh-
dc.contributor.googleauthorYeun Kim-
dc.contributor.googleauthorYoung Mi Kim-
dc.contributor.googleauthorVignesh Rajan-
dc.contributor.googleauthorSharon Y. Wong-
dc.contributor.googleauthorIsdore Chola Shamputa-
dc.contributor.googleauthorMatthew Carroll-
dc.contributor.googleauthorLisa Goldfeder-
dc.contributor.googleauthorSong A. Lee-
dc.contributor.googleauthorSteven M. Holland-
dc.contributor.googleauthorSeokyong Eum-
dc.contributor.googleauthorHyeyoung Lee-
dc.contributor.googleauthorClifton E. Barry III-
dc.identifier.doi10.1128/JCM.01476-09-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA00705-
dc.contributor.localIdA03824-
dc.relation.journalcodeJ01325-
dc.identifier.eissn1098-660X-
dc.identifier.pmid20032248-
dc.contributor.alternativeNameKim, Young Mi-
dc.contributor.alternativeNameCho, Sang Nae-
dc.contributor.affiliatedAuthorKim, Young Mi-
dc.contributor.affiliatedAuthorCho, Sang Nae-
dc.citation.volume48-
dc.citation.number2-
dc.citation.startPage402-
dc.citation.endPage411-
dc.identifier.bibliographicCitationJOURNAL OF CLINICAL MICROBIOLOGY, Vol.48(2) : 402-411, 2010-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Microbiology (미생물학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Medical Research Center (임상의학연구센터) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.